Key facts
- This page summarizes Roger Garceau's Form 4 filing for Protara Therapeutics, Inc. (TARA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2022, 16:10.
Roger Garceau - 08 Jun 2022 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)
- Reporting relationship
- Director
- Issuer ticker
- TARA
- Reported as of
- 08 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2022, 16:10:18 UTC
- Prior SEC filing
- 11 Jan 2022
- Next SEC filing
- 04 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jesse Shefferman, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Roger Garceau filed Form 4 for Protara Therapeutics, Inc. (TARA) on 09 Jun 2022.
Change
- Previous filing in this sequence was filed on 11 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TARA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 08 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $3.50
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.